Smith & Nephew plc (NYSE:SNN) Shares Sold by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC trimmed its position in shares of Smith & Nephew plc (NYSE:SNN) by 10.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 125,000 shares of the medical equipment provider’s stock after selling 15,000 shares during the period. Smith & Nephew accounts for 1.6% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 27th biggest holding. Sivik Global Healthcare LLC’s holdings in Smith & Nephew were worth $3,073,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP raised its position in Smith & Nephew by 58.2% during the second quarter. Dimensional Fund Advisors LP now owns 524,602 shares of the medical equipment provider’s stock valued at $12,995,000 after buying an additional 193,046 shares during the period. Marshall Wace LLP lifted its position in Smith & Nephew by 257.1% in the 2nd quarter. Marshall Wace LLP now owns 102,722 shares of the medical equipment provider’s stock worth $2,545,000 after buying an additional 73,960 shares in the last quarter. Creative Planning lifted its holdings in shares of Smith & Nephew by 27.0% during the 2nd quarter. Creative Planning now owns 48,474 shares of the medical equipment provider’s stock valued at $1,201,000 after buying an additional 10,307 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in Smith & Nephew in the second quarter valued at approximately $627,000. Finally, GAMMA Investing LLC grew its position in Smith & Nephew by 160.0% in the third quarter. GAMMA Investing LLC now owns 2,257 shares of the medical equipment provider’s stock worth $70,000 after acquiring an additional 1,389 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew Price Performance

SNN opened at $25.59 on Thursday. The business has a 50 day moving average of $25.03 and a 200-day moving average of $27.69. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. Smith & Nephew plc has a 1-year low of $23.65 and a 1-year high of $31.72.

Wall Street Analyst Weigh In

SNN has been the subject of a number of recent research reports. StockNews.com cut shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Berenberg Bank lowered Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, Deutsche Bank Aktiengesellschaft downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a report on Friday, November 1st.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.